The director of the Federal Research Center for Virology and Microbiology on the air of the NSN urged not to fear that the patient will not come for a second injection. The need for the second stage of vaccination against COVID-19 increases the risks that a person will not come for vaccination a second time and will nullify the effect of the administration of the drug, Anch Baranova, professor at the School of Systems Biology at George Mason University, told RIA Novosti. Director of the Federal Research Center for Virology and Microbiology Denis Kolbasov said on the air of the NSN that this should not be feared. Vektor spoke about the impact of influenza vaccination on vaccination against COVID-19 “Vaccination will be funded from the federal budget. It is the responsibility of the state to ensure vaccination in a way that is cost effective. It is difficult to imagine that a person came to the first vaccination and then got lost. This is probably the least of the problems that exist now,”he said. Kolbasov also told why it was necessary to re-vaccinate, if other vaccinations do not require it. “The flu vaccine is produced using a different technology. It is more effective, but less secure. The developers did not take this path, taking into account the new requirements for the safety of the vaccine. Safety requires double vaccination, which enhances the immune response, "- said the scientist. Earlier, the specialists of the "Vector" center said that after being vaccinated with the "EpiVacCorona" vaccine, you should not overcool, overheat and drink alcohol for three weeks. It is also important that the person is relatively healthy and that diabetes or cardiovascular disease is not a contraindication for vaccination. The nearest date for the introduction of the vaccine into civilian circulation is expected on December 10, vaccination against coronavirus will be free for Russians. On the eve of the Novosibirsk center "Vector" began the third phase of testing the vaccine against the coronavirus "EpiVacCorona". Regional medical institutions have already received the vaccine and doctors have begun recruiting volunteers to conduct post-registration studies.
